CD274 and triple-negative breast carcinoma: This contention is supported by the findings of a recent randomized, stage 3 prospective study, which showed that the combination of atezolizumab plus nab-paclitaxel was associated with a prolongation of PFS “among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1–positive subgroup” (135).